Vici Varghese is a holder of a Ph.D. degree. From March 2007 to September 2007, he served at Washington University School of Medicine, St. Louis, MO, USA, where he designed and delivered shRNA to inhibit expression of Human T-cell Leukemia Virus type I (HTLV1) tax protein using lentivirus vector in MT2 cells. Since September 2007 and till present, he has been working at the Division of Infectious Diseases, Department of Medicine, Stanford University, Palo Alto, CA, USA, where he characterized HIV-1 quasi-species in clinical samples from patients with well-defined antiretroviral treatment histories using Roche-454 next generation sequencing. 454 sequencing was used to detect minority drug resistance mutations within the virus population of a patient, and he developed panel of infectious molecular HIV-1 clones with high-level resistance to protease inhibitors, from clinical samples. He obtained his M.S. degree in environmental sciences from Cochin University of Science and Technology, India, 1998, and his Ph.D. degree in virology from the National Institute of Cholera & Enteric Diseases (NICED), Jadavpur University, Kolkata, India, 2005. His research interests include molecular characterization of Group A rotaviruses circulating in Eastern India as part of national rotavirus surveillance program, assessment of genetic diversity of human and non-human origin and possible contribution of zoonotic transmission in their diversity, and bacterial diseases management in the aquaculture hatchery system with bacterins and immunomodulants.
Biography Updated on 18 July 2013